ArticleBioengineering (Basel, Switzerland)2026
Optimized Platelet-Rich Plasma Preparations for a Consistently High Platelet Capture Rate, Bioformulation Flexibility, and Red Blood Cell Reduction Using a Single-Spin Device.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Are Platelet Volume, Density, and the Homeostatic Blueprint the Missing Link in Platelet-Rich Plasma Therapies? An Evidence-Based Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The preparation of platelet-rich plasma (PRP) requires precise density-based centrifugation of anticoagulated whole blood to achieve an optimal hematologic bioformulation while enhancing platelet recovery efficiency. Commercial PRP systems exhibit substantial heterogeneity in processing architecture, with variable platelet yields and inconsistent cellular composition profiles. In this clinical PRP device evaluation, 70 sequential samples sourced from two independent clinical facilities were used to evaluate the performance characteristics of the XCELL 60 mL single-spin centrifugation platform. Two different PRP preparations were consistently prepared as per physician preferences: PRP-1 and PRP-2. The main differences between these two preparations were the concentration of leukocytes and reduction in red blood cells. The system was evaluated based on critical PRP performance metrics. The results demonstrated the following: (1) A consistent 8-fold increase in platelet concentration relative to baseline whole blood was achieved. (2) The average platelet capture rate (PCR) was 83%. (3) The total available platelets (TAPs) in the PRP specimen produced from both groups combined were 10.8 ± 2595 billion platelets within a final product volume of 6 mL. (4) Hematocrit values were reduced to <2-6% across sites (reduction of 94% and 84% in RBCs, respectively). Finally, (5) a customizable leukocyte content (20.9-25.4 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.